The Secretary must review the data on scheduling these products
What the document says“review the relevant data pertaining to the scheduling of products containing a combination of buprenorphine and naloxone that have been approved under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355)”
The section directs the Secretary to review, consistent with sections 201 and 202 of the Controlled Substances Act, the data on the scheduling of approved products combining buprenorphine and naloxone.
What the document actually says“review the relevant data pertaining to the scheduling of products containing a combination of buprenorphine and naloxone that have been approved under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355)”
The Secretary must look at the data. The data is about how these drugs are listed. The drugs mix buprenorphine and naloxone.
Federal law sorts controlled drugs into lists called schedules. The list a drug is on sets how tightly it is held. This pair of drugs is used to treat addiction.
No action is recorded against this proposal. That is not evidence that none has been taken, and nobody has yet read it against the record. See what the tracker does not yet cover.